This module enables investors to look at Loxo Oncology various fundamental indicators over time in order to gain insight into the company future performance. Macroaxis historical fundamental analysis tools allow evaluation of not only typical financial statement drivers such as Operating Expenses of 42.4 M, Preferred Dividends Income Statement Impact of 40 K or Research and Development Expense of 30.1 M, but also many exotic indicators such as Total Assets Per Share of 9.462, Quick Ratio of 60.303 or Net Current Assets as percentage of Total Assets of 115. This module is a perfect complement to use when analyzing Loxo Oncology Valuation or Volatility. It can also complement various Loxo Oncology Technical models. Please see also analysis of Loxo Oncology Correlation with competitors.